Precision Oncology Market Report and Forecast 2025-2034
Description
The global precision oncology market size was valued at USD 107.82 Billion in 2024, driven by the increasing recognition as a reliable treatment for cancer across the globe. The market size is anticipated to grow at a CAGR of 9.80% during the forecast period of 2025-2034 to achieve a value of USD 274.61 Billion by 2034.
Precision Oncology: Introduction
Precision oncology is also known as personalized oncology. It is a rapidly advancing and innovating industry that focuses on generating personalized cancer treatment strategies depending upon a patient's unique genetic profile. Advanced techniques to diagnose the tumour or cancer are used, as genomic sequencing and molecular profiling. All these approaches help in the selection of techniques and therapies which could perform effectively for the patient. It recognizes that cancer is a complex and heterogeneous disease, and each patient's cancer may be different in nature and have unique molecular alterations.
By utilizing advanced technologies, such as genomic sequencing, proteomics, and molecular profiling, precision oncology enables the identification of that drive tumor growth and progression. With the help of advanced technologies such as genetic mutations, alterations, and biomarkers, the tumor growth could be identified and treated on time.
Global Precision Oncology Market Analysis
Precision oncology is the process in which profiling of tumour or cancer is done on the molecular level to recognize the abnormalities that can be targeted. Precision oncology is rapidly growing and has also entered the mainstream clinical approaches. Genomic testing involves several levels on which coordinated practices are performed in order to achieve high quality results out of high-quality tissue samples so that a suitable treatment can be generated for the patient.
There are several key trends aiding the global precision oncology market growth and some of them include the rapid advancements in genomic technologies, increasing availability of targeted therapies, integration of AI and machine learning to analyze and process large amount of genomic and clinical data, circulating tumour DNA and liquid biopsies, integration with clinical approaches. There is an increasing focus on the development of companion diagnostics and biomarker-driven therapies.
The increase in collaborations and partnerships are emerging as a prominent trend in precision oncology market expansion. Pharmaceutical companies, diagnostic companies, research institutions, and healthcare providers are making strategic tie-ups to accumulate resources, expertise, and data. These collaborations will enhance the development and validation of precision oncology technologies, promote knowledge sharing, and drive the adoption of precision medicine approaches in routine clinical practice.
Global Precision Oncology Market Segmentations
The EMR’s report titled “Precision Oncology Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
The market for precision oncology is witnessing an evident growth and is expected to keep growing in coming years as the industry is getting more familiar and has been advancing as a reliable treatment for cancer. This treatment provides an exclusive and intense care procedure for cancer patients by taking advantage of molecular information in order to prepare and instruct personalised treatments. Increasing prevalence of cancer across the globe has been driving the precision oncology market development as it is leading to the increasing demand for personalised and effective cancer treatments. As a challenge, the high cost of genomic profiling along with multiple other factors regarding high quality and robust evidence to support the efficacy of developed tailored therapies also stays in the market.
Precision Oncology Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Precision Oncology: Introduction
Precision oncology is also known as personalized oncology. It is a rapidly advancing and innovating industry that focuses on generating personalized cancer treatment strategies depending upon a patient's unique genetic profile. Advanced techniques to diagnose the tumour or cancer are used, as genomic sequencing and molecular profiling. All these approaches help in the selection of techniques and therapies which could perform effectively for the patient. It recognizes that cancer is a complex and heterogeneous disease, and each patient's cancer may be different in nature and have unique molecular alterations.
By utilizing advanced technologies, such as genomic sequencing, proteomics, and molecular profiling, precision oncology enables the identification of that drive tumor growth and progression. With the help of advanced technologies such as genetic mutations, alterations, and biomarkers, the tumor growth could be identified and treated on time.
Global Precision Oncology Market Analysis
Precision oncology is the process in which profiling of tumour or cancer is done on the molecular level to recognize the abnormalities that can be targeted. Precision oncology is rapidly growing and has also entered the mainstream clinical approaches. Genomic testing involves several levels on which coordinated practices are performed in order to achieve high quality results out of high-quality tissue samples so that a suitable treatment can be generated for the patient.
There are several key trends aiding the global precision oncology market growth and some of them include the rapid advancements in genomic technologies, increasing availability of targeted therapies, integration of AI and machine learning to analyze and process large amount of genomic and clinical data, circulating tumour DNA and liquid biopsies, integration with clinical approaches. There is an increasing focus on the development of companion diagnostics and biomarker-driven therapies.
The increase in collaborations and partnerships are emerging as a prominent trend in precision oncology market expansion. Pharmaceutical companies, diagnostic companies, research institutions, and healthcare providers are making strategic tie-ups to accumulate resources, expertise, and data. These collaborations will enhance the development and validation of precision oncology technologies, promote knowledge sharing, and drive the adoption of precision medicine approaches in routine clinical practice.
Global Precision Oncology Market Segmentations
The EMR’s report titled “Precision Oncology Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
- Diagnostics
- Therapeutics
- Others
- Breast Cancer
- Cervical Cancer
- Prostate Cancer
- Lung Cancer
- Hospitals
- Specialty Clinic
- Pharmaceutical and Biotechnology Companies
- Healthcare Data Companies
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The market for precision oncology is witnessing an evident growth and is expected to keep growing in coming years as the industry is getting more familiar and has been advancing as a reliable treatment for cancer. This treatment provides an exclusive and intense care procedure for cancer patients by taking advantage of molecular information in order to prepare and instruct personalised treatments. Increasing prevalence of cancer across the globe has been driving the precision oncology market development as it is leading to the increasing demand for personalised and effective cancer treatments. As a challenge, the high cost of genomic profiling along with multiple other factors regarding high quality and robust evidence to support the efficacy of developed tailored therapies also stays in the market.
Precision Oncology Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific Inc.
- Invitae Corporation
- Qiagen N.V.
- Illumina, Inc.
- Laboratory Corporation Of America Holding
- Exact Sciences Corporation
- Rain Oncology Inc
- Strata Oncology, Inc.
- Xilis, Inc.
- Variantyx, Inc.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Precision Oncology Market Overview
- 3.1 Global Precision Oncology Market Historical Value (2018-2024)
- 3.2 Global Precision Oncology Market Forecast Value (2025-2034)
- 4 Global Precision Oncology Market Landscape
- 4.1 Global Precision Oncology: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Precision Oncology: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Drug
- 4.2.3 Analysis by Indication
- 5 Global Precision Oncology Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Precision Oncology Market Segmentation
- 6.1 Global Precision Oncology Market by Service Type
- 6.1.1 Market Overview
- 6.1.2 Diagnostics
- 6.1.3 Therapeutics
- 6.1.4 Others
- 6.2 Global Precision Oncology Market by Cancer Type
- 6.2.1 Market Overview
- 6.2.2 Breast Cancer
- 6.2.3 Cervical Cancer
- 6.2.4 Prostate Cancer
- 6.2.5 Lung Cancer
- 6.3 Global Precision Oncology Market by End User
- 6.3.1 Market Overview
- 6.3.2 Hospitals
- 6.3.3 Specialty Clinic
- 6.3.4 Pharmaceutical and Biotechnology Companies
- 6.3.5 Healthcare Data Companies
- 6.3.6 Others
- 6.4 Global Precision Oncology Market by Region
- 6.4.1 Market Overview
- 6.4.2 North America
- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America Precision Oncology
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Precision Oncology Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Precision Oncology Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Precision Oncology Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Precision Oncology Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Clinical Trials Analysis
- 15.1 Analysis by Trial Registration Year
- 15.2 Analysis by Trial Status
- 15.3 Analysis by Trial Phase
- 15.4 Analysis by Therapeutic Area
- 15.5 Analysis by Geography
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Type of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Partnership and Collaborations Analysis
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Type of Partnership
- 17.3 Analysis by Leading Players
- 17.4 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Thermo Fisher Scientific Inc.
- 18.1.1 Financial Analysis
- 18.1.2 Product Portfolio
- 18.1.3 Demographic Reach and Achievements
- 18.1.4 Mergers and Acquisitions
- 18.1.5 Certifications
- 18.2 Invitae Corporation
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Mergers and Acquisitions
- 18.2.5 Certifications
- 18.3 Qiagen N.V.
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Mergers and Acquisitions
- 18.3.5 Certifications
- 18.4 Illumina, Inc.
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Mergers and Acquisitions
- 18.4.5 Certifications
- 18.5 Laboratory Corporation Of America Holding
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Mergers and Acquisitions
- 18.5.5 Certifications
- 18.6 Exact Sciences Corporation
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Mergers and Acquisitions
- 18.6.5 Certifications
- 18.7 Rain Oncology Inc
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Mergers and Acquisitions
- 18.7.5 Certifications
- 18.8 Strata Oncology, Inc.
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Mergers and Acquisitions
- 18.8.5 Certifications
- 18.9 Xilis, Inc.
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Mergers and Acquisitions
- 18.9.5 Certifications
- 18.10 Variantyx, Inc.
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Mergers and Acquisitions
- 18.10.5 Certifications
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
